Talking to Your Neurologist About DMTs

What Are Disease-Modifying Therapies?

Disease-modifying therapies (DMTs) are medications that reduce the frequency and severity of MS relapses and slow the accumulation of disability over time. They do not repair existing damage or eliminate symptoms — but they are the most powerful tools available for changing the long-term course of the disease.

As of 2026, over 20 FDA-approved DMTs exist for relapsing forms of MS, with several approved for primary progressive MS (PPMS) as well. They range from once-daily pills to monthly infusions, and from mild immune modulation to aggressive immune reconstitution. Choosing the right one involves balancing efficacy, safety, lifestyle, and personal values — which is why the conversation with your neurologist matters so much.

The Efficacy Spectrum

DMTs are broadly categorized by their efficacy level:

Moderate-efficacy therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide) reduce relapse rates by roughly 30–50% compared to placebo. They have long safety records and are often used as first-line treatments for people with milder disease activity.

High-efficacy therapies (natalizumab, ocrelizumab, ofatumumab, cladribine, alemtuzumab) reduce relapse rates by 50–80% or more. They carry higher risks but are increasingly used earlier in the disease course, particularly for people with aggressive MS or significant disability risk.

The "treat to target" debate — Many neurologists now advocate starting with high-efficacy therapy early ("escalation vs. induction" debate), arguing that the window to prevent irreversible disability is narrow. Others prefer starting moderate and escalating if needed. There is no universal right answer — it depends on your disease activity, risk tolerance, and life circumstances.

Questions to Ask Your Neurologist

Going into a DMT conversation prepared makes a significant difference. Consider asking:

About your disease: "What does my MRI show about my disease activity?" "Am I at high risk for disability progression?" "What would you recommend if I were your family member?"

About the therapy: "What is the relapse reduction rate for this medication?" "What are the most common side effects, and how are they managed?" "What are the rare but serious risks?" "How long before I'd know if it's working?"

About monitoring: "What tests will I need while on this medication?" "How often will we do MRIs?" "What symptoms should prompt me to call your office immediately?"

About lifestyle: "Does this medication interact with vaccines?" "Can I get pregnant on this therapy?" "Does it affect my ability to work or travel?"

About alternatives: "What happens if I choose not to treat right now?" "What are my options if this therapy stops working?"

Understanding Risk Tolerance

Every DMT involves a trade-off between efficacy and risk. The most effective therapies tend to carry the most significant risks. For example:

Natalizumab (Tysabri) is highly effective but carries a risk of PML (progressive multifocal leukoencephalopathy), a rare but potentially fatal brain infection caused by the JC virus. Risk is stratified by JC antibody status and duration of treatment — your neurologist will monitor this closely.

Alemtuzumab (Lemtrada) can produce near-complete immune reconstitution but causes secondary autoimmune conditions in about 30% of patients (thyroid disease, immune thrombocytopenia) that require ongoing monitoring for years.

Ocrelizumab (Ocrevus) and ofatumumab (Kesimpta) deplete B cells and are highly effective, but suppress immune responses to vaccines and increase infection risk.

Your risk tolerance is personal. A 35-year-old with aggressive MS and two young children may make a very different calculation than a 60-year-old with stable disease. Neither choice is wrong — but it should be informed.

Advocating for Yourself

Neurologists see many patients and have limited appointment time. To get the most from your visit:

Bring a written list of questions — prioritized, with the most important first. Neurologists respect prepared patients and it signals that you're engaged in your care.

Bring a support person — a partner, family member, or friend can help remember information, ask follow-up questions, and provide emotional support during difficult conversations.

Request a longer appointment if you're newly diagnosed or considering a major treatment change. Many practices offer extended consultations.

Ask for written materials — reputable resources include the National MS Society (nationalmssociety.org), the MS Association of America, and the manufacturer's patient education materials.

Get a second opinion if you're uncertain. MS treatment decisions are significant, and most neurologists support patients seeking additional perspectives, especially at major decision points.

If You're Newly Diagnosed

A new MS diagnosis is overwhelming, and the pressure to make a treatment decision quickly can feel immense. A few things to know:

Most neurologists recommend starting a DMT promptly after a confirmed diagnosis of relapsing MS — early treatment is associated with better long-term outcomes. However, "promptly" typically means within weeks to a few months, not hours. You have time to ask questions, do research, and feel confident in your decision.

You are not alone in this. The MS Together community includes thousands of people who have navigated these exact decisions. Sharing experiences — what worked, what didn't, what questions they wished they'd asked — is one of the most valuable things our community offers.